Pharma BD Deal Intelligence
Teva Pharmaceuticals International GmbH and Polpharma Biologics International AG announced a global licensing agreement granting Teva exclusive rights to commercialise both intravenous and subcutaneous formulations of Polpharma's proposed ocrelizumab biosimilar PB018, a biosimilar candidate to Roche's Ocrevus for multiple sclerosis, upon regulatory approval. Polpharma Biologics retains full responsibility for development and manufacturing; Teva is responsible for regulatory submissions and commercialisation in the United States, Europe, Brazil, Canada, Australia, New Zealand, Israel and Turkey. PB018 is in early development and had not entered clinical trials at signing, with a Phase 1 study versus Ocrevus planned to start in October 2026. Financial terms were not disclosed. Teva framed the deal as advancing its Pivot to Growth strategy by expanding the biosimilars pipeline.
← Browse all deals · How we score deals
More: 2026 deals · Teva Pharmaceutical Industries Ltd. deals